Terms ending in 2032
Every in-force patent on Abbott Laboratories's record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,708,968 | Removal of Needle Shields from Syringes and Automatic Injection Devices In force · High confidence | Elcam Medical Agricultural Cooperative Association Ltd. | In force | High confidence | |
| US 9,265,887 | Automatic Injection Devices Having Overmolded Gripping Surfaces In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US D777,048 | Diagnostic Analyzer In force · High confidence | Abbott Laboratories | In force | High confidence | |
| US D777,049 | Diagnostic Analyzer In force · High confidence | Abbott Laboratories | In force | High confidence | |
| US 8,722,657 | Salts and Crystalline Forms of an Apoptosis-Inducing Agent In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 8,609,674 | Potassium Channel Modulators In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 8,962,639 | Potassium Channel Modulators In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 8,889,130 | Treatment of Osteoarthritis and Pain In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 8,691,810 | Pyrrolopyridine and Pyrrolopyrimidine Inhibitors of Kinases In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 8,710,065 | Tricyclic Inhibitors of Kinases In force · High confidence | AbbVie Inc. | In force | High confidence | |
| 62 more term ends in 2032 · Pro | |||||
10 of 72 patents shown. Soonest term end first, then patent number.
Pro members see all 72.
42 of these are in force and held by Abbott Laboratories.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.